New publication: GNE genotype explains 20% of phenotypic variability in GNE myopathy

A lack of genotype-phenotype correlations in many neuromuscular disorders can make it difficult for doctors to manage diseases and give advice on prognosis and disease trajectory to patients. In addition, it may hinder clinical research. Our most recent paper by Pogoryelova et al, a systematic review and meta-analysis, examines this problem and demonstrates that key aspects of the disease, like loss of ambulation, are influenced by the precise gene mutation. This information will be useful to treating physicians and should be taken into account when designing clinical trials.

Read the full article here (Open access)

GNE myopathy is a rare muscle disorder that usually presents with foot drop and distal weakness in young adults and progresses to loss of ambulation over the course of 10 to 20 years. The condition, caused by different mutations in the GNE gene, is found world-wide, but has a higher incidence in populations with founder mutations such as the Middle-East and Japan. Most mutations including the founder mutations in Israel and Japan are missense mutations that are expected to reduce the enzymatic activity or abundance of the GNE protein to different degrees. However, wide phenotypic variability has been observed even for patients carrying the same GNE mutation, with onset ranging from 10 years to 60 years of age. Our study used 2 data sources – from published literature and from the GNE registry – where both clinical information, e.g. age of onset, and genetic information, e.g. the causative variants in the GNE gene, were provided on an individual basis to determine the contribution of the GNE mutation itself vs other factors to the phenotypic variability. Through statistical analysis and modeling we were able to show that, while the GNE mutation remains the genetic cause of GNE myopathy, the GNE genotype explains only about 20% of phenotypic variability observed. This suggests that currently unknown, potent modifiers – genetic, epigenetic or environmental – contribute to the severity of GNE myopathy. Further research in well characterized patient cohorts may be able to identify those factors, potentially opening new avenues for therapeutic interventions.

GNE genotype explains 20% of phenotypic variability in GNE myopathy
Oksana Pogoryelova, Ian J. Wilson, Hank Mansbach, Zohar Argov, Ichizo Nishino, Hanns Lochmüller
Neurol Genet. 2019.5 (1)e308
PMID:30842975

Abstract

Objective

To test the hypothesis that common GNE mutations influence disease severity; using statistical analysis of patient cohorts from different countries.

Methods

Systematic literature review identified 11 articles reporting 759 patients. GNE registry data were used as a second data set. The relative contributions of the GNE mutations, homozygosity, and country to the age at onset were explored using linear modeling, and relative importance measures were calculated. The rate of ambulation loss for GNE mutations, homozygosity, country, and age at onset was analyzed using Cox proportional hazards models.

Results

A spectrum of symptoms and large variability of age at onset and nonambulatory status was observed within families and cohorts. We estimated that 20% of variability is explained by GNE mutations. Individuals harboring p.Asp207Val have an expected age at onset 8.0 (s.e1.0) years later than those without and probability of continued ambulation at age 40 of 0.98 (95% confidence interval [CI] 0.96–1). In contrast, p.Leu539Ser results in onset on average 7.2 (s.e.2.7) years earlier than those without this mutation, and p.Val603Leu has a probability of continued ambulance of 0.61 (95% CI 0.50–0.74) at age 40, but has a nonsignificant effect on age at onset.

Conclusions

GNE myopathy severity significantly varies in all cohorts, with 20% of variability explained by the GNE mutation. Atypical symptoms and clinical presentation suggest that physical and instrumental examination should include additional clinical tests. Proven and measurable effect of GNE mutations on the disease severity should be factored in patient management and clinical research study for a better data interpretation.

GNE biopsy

Read next...

https://lochmullerlab.org/files/cropped-LochmullerLab_web.jpg

Lochmüller Lab Welcomes New Students

Our lab is growing! We are excited to introduce two new students who have joined the Lochmüller Lab this fall.   Kelly Ho Kelly has...
JND8-4_announcement

Latest Issue of the Journal of Neuromuscular Diseases Now Available – July 2021

The Journal of Neuromuscular Diseases (JND) has announced the publication of a new issue of the journal!     Volume 8, Issue 4 of the JND contains a record number 30 items comprised...
meetClinicalTeam

Meet the Lochmüller Lab Clinical Team

Neuromuscular Clinic for adult patients at The Ottawa Hospital (TOH) Civic Campus As part of the team led by Dr. Jodi Warman Chardon, Hanns sees...
1by1treatabolome

Special issue of the Journal of Neuromuscular Diseases is devoted to the Treatabolome, designed to shorten diagnosis-to-treatment time for patients with rare diseases

In 2019, as part of the European Solve-RD project, Hanns Lochmüller, Gisèle Bonne and Rachel Thompson launched the Treatabolome, an initiative designed to extract details...
ProDGNE RGB-01

ProDGNE: Research Project to Develop an Innovative Therapeutic Compound to Treat GNE Myopathy

The Lochmüller Lab is proud to share its involvement in ProDGNE , a three-year transnational pre-clinical research project which aims to develop an innovative therapeutic...
Neuromuscular junction and animal models

Meet the lab’s two new members

Our lab is growing! We are excited to introduce two new members who have joined the Lochmüller lab this winter. Daniel O'Neil Daniel holds a...